<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946305</url>
  </required_header>
  <id_info>
    <org_study_id>CAAA601A12403</org_study_id>
    <nct_id>NCT04946305</nct_id>
  </id_info>
  <brief_title>A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea</brief_title>
  <official_title>A Post Marketing Surveillance on Lutathera® (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, multi-center, non-comparative, non-interventional&#xD;
      observational study to assess safety and effectiveness of Lutathera in patients with&#xD;
      somatostatin receptor-positive GEP-NET in the real-world setting in Korea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Incidence of Adverse Events (AEs), Serious AE and unexpected AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Drug Reactions</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Incidence of Adverse Drug Reactions (ADRs), Serious ADRs and unexpected ADRs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness in terms of Overall Response Rate (ORR)</measure>
    <time_frame>Up to 32 weeks (4 cycles of 8 weeks)</time_frame>
    <description>ORR is defined as the proportion of treated patients who achieve a best overall response of partial response (PR) or complete response (CR) according to RECIST 1.1.&#xD;
Partial Response (PR): At least a 30% decrease from baseline, confirmed at 4 weeks.&#xD;
Complete Response (CR): Disappearance of all known disease, confirmed at 4 weeks, lymph nodes must be less than 10 mm short axis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Somatostatin Receptor-positive GEP-NET</condition>
  <arm_group>
    <arm_group_label>Lutathera</arm_group_label>
    <description>Patients administered Lutathera by prescription</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lutathera</intervention_name>
    <description>Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>Lutathera</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who start Lutathera treatment per clinical judgment, according to the locally&#xD;
             approved labeling.&#xD;
&#xD;
             - somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors&#xD;
             (GEP-NETs) in adults.&#xD;
&#xD;
          2. Patients who are willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients with contraindication according to prescribing information for Lutathera in&#xD;
        Korea.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>somatostatin receptor-positive GEP-NET</keyword>
  <keyword>Lutathera</keyword>
  <keyword>Observational</keyword>
  <keyword>prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lutetium Lu 177 dotatate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

